As of July 23, 2025, the new version of the ICH E6(R3) guideline comes into force, a key document marking a before and after in how clinical studies are managed globally. This revision reinforces essential concepts such as quality by design, risk-based approaches, and, most notably, the validation of computerized systems used throughout the study.
In this article, we review the essential points marking a turning point in clinical trial regulation.
A new approach for a new digital reality
Increasing digitalization has transformed how trials are managed and executed. Today, tools such as eCRF platforms, mobile apps for ePRO, remote sensors, EHR, or randomization algorithms are not technological accessories: they are central elements in the generation, processing, and analysis of clinical data.
In this new context, this guideline explicitly recognizes the central role of digital systems in today's GCP environment, where validation is non-negotiable. It is the way to guarantee that a system does what it is supposed to do, in a reliable, reproducible, and secure manner within its real environment of use.
Why so much emphasis on validation?
One of the fundamental objectives of this regulatory update is to ensure that clinical data are integral, complete, traceable, and recoverable, because clinical decisions are based on data. Therefore, it is essential that systems managing them are properly validated, preventing the validity of the study from being called into question.
Validating means demonstrating, with sufficient evidence, that a system does what it is supposed to do, reliably, in its real environment of use. But not all systems require the same level of validation: ICH E6(R3) does not prescribe a single validation format, but it does make clear that it must be proportional to the risk represented by the system.
A system directly impacting the capture, processing, or analysis of clinical data requires more robust validation than a system without direct impact on data integrity. The greater the system's impact on quality or data integrity, the higher the level of control required.
A look toward real compliance
The new revision of the guideline reinforces the need for all involved stakeholders, especially sponsors, to maintain active oversight over the systems used, promoting a collaborative approach with sites and vendors. It is no longer enough to delegate compliance: it must be integrated and demonstrated.
This implies:
The ultimate goal is not to accumulate paperwork, but to ensure that data collected during the trial are reliable and can withstand inspection scrutiny. Real compliance requires an integrated approach combining technical expertise, regulatory knowledge, and analytical capability. This is where expert guidance becomes key.
With this new guideline, a clear message is consolidated: system validation is no longer a formality. It is a key piece of the quality system supporting the clinical study. Understanding this is essential for compliance, but also for building trust in research findings.
Connect with experts
ICH E6(R3) does not come to increase bureaucracy, but to promote more efficient and risk-aware management. Validation is no longer just a technical requirement, but a strategic piece of the quality system supporting the clinical trial.
At Ambit Iberia, we have been experts for over 20 years in developing strategies and IT solutions. We help the pharmaceutical, medical device, and IVD (in vitro diagnosis) medical device sectors comply with regulations throughout the product lifecycle. We design and implement innovative infrastructures thanks to a comprehensive service offering acting as a key enabler for digital transformation.
We offer consulting, auditing, and specialized training services to help you excel in the regulated sector. Click here to get in touch with us.